CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Johnson & Johnson (JNJ) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Johnson & Johnson (JNJ)

Pharmaceutical Preparations · market cap $649.6B · as of 2026-10-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-12-15 (est.)
Phase 3
Pipeline
20
programs
Upcoming events
7
next 90d+
Dossier
Ready
cached
Johnson & Johnson is a large-cap, AAA-rated (S&P) pharmaceutical, biotech and medtech company with a ~$642B market cap and 2025 revenue of $94.2B. CatalystAlert's database lists 29 pipeline entries, with Phase 3 programs concentrated in multiple myeloma, NSCLC, bladder cancer, immunology and psychiatry. Our calendar shows six estimated Phase 2/3 readouts between April and September 2027, and the most recent tagged event, 2026-10-13 earnings, is marked negative.
The catalyst path
  • 2026-12-15 (est.)Phase 3 · Nipocalimabimp 9/10
  • 2027-02-04 (est.)Phase 3 · Nipocalimabimp 9/10
  • 2027-04-27 (est.)Phase 2 · Amivantamab IVimp 7/10
  • 2027-07-30 (est.)Phase 3 · Daratumumabimp 9/10
  • 2027-08-15 (est.)Phase 2 · Teclistamabimp 7/10
  • 2027-08-17 (est.)Phase 2 · Amivantamabimp 7/10
  • 2027-09-28 (est.)Phase 3 · Nipocalimabimp 9/10
Pipeline
AssetPhaseIndication
galantamine ERPhase 3Alzheimer's Disease
R228060Phase 2Major Depressive Disorder
Test acetaminophenPhase 3Post-operative Dental Pain
Experimental Product Colloidal Oatmeal BalmPhase 2Atopic Dermatitis
CG 5503;tapentadolPhase 3Osteoarthritis
tapentadol (CG5503) ERPhase 3Low Back Pain
JNJ-90301900Phase 2Carcinoma, Non-Small-Cell Lung
levofloxacinPhase 3Pneumonia
JNJ16269110Phase 2Diabetes Mellitus, Type 2
RivaroxabanPhase 3Atrial Fibrillation
ibuprofen; pseudoephedrine HClPhase 2Enuresis
tapentadol (CG5503) Immediate Release IRPhase 3Low Back Pain
Acetaminophen/Naproxen Sodium Fixed CombinationPhase 3Pain
Paliperidone extended-releasePhase 3Bipolar Disorder
Risperdal ConstaPhase 3Bipolar Disorder
Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD)Phase 3Multiple Myeloma
paliperidone ER OrosPhase 3Schizophrenia
Gemcitabine with R115777Phase 3Pancreatic Neoplasms
tapentadol HClPhase 2Pain
MebendazolePhase 3Healthy Volunteers
Price & technical context
3-month
+5.5%
6-month
+24.9%
12-month
+46.5%
52-wk range
$195.93–$286.02
vs 50-day MA
+7.1%
vs 200-day MA
+14.4%
Realized vol
21.1%
Max drawdown
-14.3%

Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for JNJ (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.